Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider
Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel Unprecedented Market Expansion.
Austin, United States, March 17, 2026 (GLOBE NEWSWIRE) — Predictive Biomarkers Market Size & Growth Analysis:
According to SNS Insider, The Predictive Biomarkers Market size is estimated at USD 28.80 Billion in 2025 and is expected to reach USD 156.85 Billion by 2035, growing at a CAGR of 18.47% over 2026-2035.High adoption of precision medicine, increased prevalence of chronic diseases, and high demand for targeted therapeutics are key factors fueling the growth of global predictive biomarkers market.
Market Size and Forecast:
- Market Size in 2025: USD 28.80 Billion
- Market Size by 2035: USD 156.85 Billion
- CAGR: 18.47% from 2026 to 2035
- Base Year: 2025
- Forecast Period: 2026–2035
- Historical Data: 2022–2024
Get a Sample Report of Predictive Biomarkers Market: https://www.snsinsider.com/sample-request/7676
The U.S. Predictive Biomarkers Market is estimated at USD 9.62 billion in 2025 and is expected to reach USD 50.31 billion by 2035, growing at a CAGR of 18.01% over 2026-2035.The global predictive biomarkers market is dominated by the cardiovascular etiology predictive biomarkers market across the U.S., owing to developed healthcare infrastructure, high pharmaceutical research capabilities, and widespread precision medicine initiatives across the country.
Rising Adoption of Precision Medicine and Targeted Therapies to Propel Market Expansion Globally
Rapid growth of precision medicine and targeted therapeutic strategies is a key factor for growth of predictive biomarkers market. If you combine predictive biomarkers with top-notch oral administration, top-notch outcomes are guaranteed and unnecessary healthcare cost is minimized, and only those who would respond to the drug will receive it. Predictive biomarkers, including genomic alterations and protein expression levels, are now being utilized to prioritize therapeutic choices for targeted and immunotherapies in oncology. Pharmaceutical industry is adopting biomarker strategies earlier in the drug development process to improve clinical trial efficiency and maximize success of regulatory approval.
Major Players Listed in this Report:
- Thermo Fisher Scientific
- Illumina Inc.
- Roche Diagnostics
- Qiagen N.V.
- Agilent Technologies
- Bio-Rad Laboratories
- PerkinElmer Inc.
- Danaher Corporation
- Abbott Laboratories
- Siemens Healthineers
- GE Healthcare
- Guardant Health
- Foundation Medicine
- Exact Sciences Corporation
- Myriad Genetics
- NeoGenomics Laboratories
- BioMérieux
- Genomic Health
- Tempus Labs
- Natera Inc.
Segmentation Analysis:
By Indication
In 2025, the largest predictive biomarkers market share, nearly 46.82% of total revenue–was captured by the cancer segment. This dominance is primarily due to the legacy of widespread application of predictive biomarkers in oncology used in identifying genetic mutations to direct targeted therapies or selecting patients for immunotherapy.The segment of neurological diseases is projected to grow at the fastest rate during the period from 2026 to 2035, registering a CAGR of 19.54%. The application of predictive biomarkers in neurology is expanding due to increasing research into both neurodegenerative disorder-associated biomarkers.
By Technology
Based on the application segment, the diagnostics accounted for the largest share of the total predictive biomarkers market, representi ng around 38.47% of the market in 2025 as predictive biomarker-driven diagnostic tests have become a standard approach for determining disease risk, treatment selection and monitoring of therapeutic responses.On the basis of segment, the personalized medicine segment registered the highest CAGR of 19.92% during the forecast period. The foundation for personalized medicine approaches is the consideration of predictive biomarkers that may allow us to individualize treatment based on genetic traits and disease characteristics.
By End User
In 2025, pharmaceutical and biotechnology companies held the largest predictive biomarkers market share of about 41.68% of total revenue. These companies are adopting predictive biomarkers to streamline both drug discovery and development processes to de-risk late-stage clinical trials and shorten regulatory approval timelines. Diagnostics and research laboratories is likely to find lucrative growth opportunities in the global single cell analysis market on the account of the rapid advancements in the field of biotechnology and therapeutics and will emerge as the fastest growing end-user segment retaining a CAGR value of 19.33% through the forecast period.
Need Any Customization Research on Predictive Biomarkers Market, Enquire Now: https://www.snsinsider.com/enquiry/7676
Predictive Biomarkers Market Segmentation
By Indication
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
By Technology
- Diagnostics
- Drug Discovery & Development
- Personalized Medicine
- Disease Risk Assessment
- Others
By End-user
- Pharmaceutical & Biotechnology Companies
- Diagnostics & Research Laboratories
- Hospitals & Specialty Clinics
- Others
Regional Insights:
Predictive Biomarkers Market in the Asia Pacific region is estimated to be the fastest-growing market at a CAGR of 19.85% from 2026 to 2035. Regional market growth is ultimately driven by rapid improvements in HC infrastructure, faster uptake of biotech research and establishment of genomic medicine programs.
The segment of predictive biomarkers market size in North America dominated the global market with 42.63% share in terms of revenue in 2025 It is likely that these market growth factors are related to the presence of leading biotechnology and pharmaceutical companies, strong academic research institutions, and supportive regulatory environments.
Developments:
- In March 2025, Thermo Fisher Scientific launched an advanced next-generation sequencing panel designed to identify predictive biomarkers across multiple cancer types, improving personalized treatment selection.
- In January 2025, Illumina Inc. introduced a high-throughput sequencing platform optimized for biomarker discovery in large-scale genomic research studies.
Exclusive Sections of the Report (The USPs):
PRICING DYNAMICS & MARGIN STRUCTURE – helps you understand distribution margins across product types, regional price variations, and evolving pricing models impacting profitability and contract strategies.
REGULATORY & COMPLIANCE FRAMEWORK – helps you evaluate adherence to global pharmaceutical regulations, cold chain standards, and policy support shaping operational efficiency and risk management.
TECHNOLOGY ADOPTION & INNOVATION METRICS – helps you identify the pace of digital transformation including AI-based forecasting, blockchain integration, and smart warehousing investments in healthcare logistics.
Predictive Biomarkers Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 28.80 Billion |
| Market Size by 2035 | USD 156.85 Billion |
| CAGR | CAGR of 18.47% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Purchase Single User PDF of Predictive Biomarkers Market Report (20% Discount): https://www.snsinsider.com/checkout/7676
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Market Overview
4. Statistical Insights & Trends Reporting
5. Predictive Biomarkers Market Segmental Analysis & Forecast, By Indication
6. Predictive Biomarkers Market Segmental Analysis & Forecast, By Technology
7. Predictive Biomarkers Market Segmental Analysis & Forecast, By End-user
8. Predictive Biomarkers Market Segmental Analysis & Forecast, By Region
9. Competitive Landscape
10. Analyst Recommendations
11. Assumptions
12. Disclaimer
13. Appendix
Browse Other Reports
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.
